Xenon Pharmaceuticals (XENE) Competitors $39.99 +0.35 (+0.88%) Closing price 04:00 PM EasternExtended Trading$39.99 0.00 (0.00%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XENE vs. VTRS, RDY, MRNA, ROIV, QGEN, ELAN, BBIO, VRNA, RVMD, and MRUSShould you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Xenon Pharmaceuticals vs. Its Competitors Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Verona Pharma PLC American Depositary Share Revolution Medicines Merus Viatris (NASDAQ:VTRS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Is VTRS or XENE more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-24.57% 16.54% 7.06% Xenon Pharmaceuticals N/A -38.50%-36.47% Which has better valuation and earnings, VTRS or XENE? Xenon Pharmaceuticals has lower revenue, but higher earnings than Viatris. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.78-$634.20M-$2.90-3.40Xenon Pharmaceuticals$9.43M327.00-$234.33M-$3.55-11.26 Which has more volatility and risk, VTRS or XENE? Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Does the media favor VTRS or XENE? In the previous week, Xenon Pharmaceuticals had 14 more articles in the media than Viatris. MarketBeat recorded 18 mentions for Xenon Pharmaceuticals and 4 mentions for Viatris. Viatris' average media sentiment score of 0.81 beat Xenon Pharmaceuticals' score of 0.72 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of VTRS or XENE? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 0.1% of Viatris shares are owned by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate VTRS or XENE? Viatris currently has a consensus price target of $10.40, suggesting a potential upside of 5.48%. Xenon Pharmaceuticals has a consensus price target of $53.67, suggesting a potential upside of 34.20%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 3 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67Xenon Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 SummaryXenon Pharmaceuticals beats Viatris on 11 of the 17 factors compared between the two stocks. Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XENE vs. The Competition Export to ExcelMetricXenon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.06B$3.35B$6.04B$10.28BDividend YieldN/A2.31%5.73%4.81%P/E Ratio-11.267.8363.5822.85Price / Sales327.00478.36612.85138.67Price / CashN/A44.9825.7330.17Price / Book4.0410.3812.666.69Net Income-$234.33M-$52.31M$3.31B$276.03M7 Day Performance1.11%0.59%-0.44%-1.13%1 Month Performance10.44%13.90%8.70%6.49%1 Year Performance-2.96%28.95%76.70%34.41% Xenon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals2.455 of 5 stars$39.99+0.9%$53.67+34.2%-3.8%$3.06B$9.43M-11.26210VTRSViatris1.9056 of 5 stars$10.13-0.6%$10.40+2.7%-14.4%$11.88B$14.74B-3.4932,000RDYDr. Reddy's Laboratories2.5305 of 5 stars$14.12-0.3%$16.95+20.0%-8.4%$11.82B$3.81B21.3927,811Positive NewsMRNAModerna4.2402 of 5 stars$27.54-3.3%$41.81+51.8%-54.0%$11.08B$3.24B-3.665,800Analyst ForecastROIVRoivant Sciences3.3525 of 5 stars$16.26+0.6%$19.94+22.6%+34.8%$11.04B$29.05M-23.23860QGENQIAGEN4.3834 of 5 stars$46.99+0.4%$49.40+5.1%+9.9%$10.40B$1.98B27.765,765Positive NewsAnalyst DowngradeELANElanco Animal Health2.5941 of 5 stars$20.68+0.2%$18.33-11.3%+37.6%$10.25B$4.44B24.059,000BBIOBridgeBio Pharma4.1438 of 5 stars$54.61+3.3%$63.94+17.1%+114.2%$10.11B$221.90M-13.35400Insider TradeVRNAVerona Pharma PLC American Depositary Share1.5476 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.20B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.0771 of 5 stars$46.58-0.3%$74.64+60.2%-4.4%$8.73B$11.58M-10.35250MRUSMerus1.0289 of 5 stars$94.270.0%$93.12-1.2%+76.7%$7.13B$56.23M-17.1437 Related Companies and Tools Related Companies Viatris Alternatives Dr. Reddy's Laboratories Alternatives Moderna Alternatives Roivant Sciences Alternatives QIAGEN Alternatives Elanco Animal Health Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Merus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XENE) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
